DBP signed a "Memorandum of Understanding" with international partner regarding a possible licensing agreement on development of Temodex
Today, the 5thof April, DBP AB has signed a so-called "Memorandum of Understanding" (MoU) with a potential partner for the development of Temodex. Development involves clinical development, manufacturing, marketing, distribution and othr product-related activities. MoU describes the cooperation terms between DBP and the upcoming partner and can potentially lead to an exclusive license agreement on the development of Temodex.
DBP builds today a portfolio of drug candidates for various types of cancers. These candidates should then be outlicensed for commercialization. Temodex - acting against brain cancer - has already been granted an Orphan drug designation by EMA, which allows to substantially shorten its time-to-market.
"We have sought an international partner for Temodex in order to take the next step in our business model towards global commercialization of Temodex, says Igor Lokot, president of DBP, - We hope to enter into a license agreement for Temodex with this partner at latest during Q3 2017. In this case we can further accelerate the development of this product and even other drug candidates in our portfolio.
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 5 of April 2017.
Temodex, which is a locally acting formulation of temozolomide, was developed by RI PCP in Minsk, Belarus, and is registered for marketing within Belarus since 2014 as the first-line treatment of glioblastoma. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Find out more here.
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. DBP acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015. The company was granted Orphan Drug Designation status by EMA for Temodex in July 2016.